We sought to describe the exposure–response relationship of necitumumab efficacy in squamous non‐small cell lung cancer patients and evaluate intrinsic and extrinsic patient descriptors that may guide dosing. SQUIRE was a phase III study comparing necitumumab in combination with gemcitabine and cisplatin vs. gemcitabine and cisplatin alone in 1,014 patients. An integrated model for tumor size dynamics and overall survival was developed, where reduction in tumor size results in a decrease in survival hazard. The change in tumor size was characterized using linear growth and first‐order shrinkage. Overall survival was described using a combination of a Weibull function and Gompertz function for the hazard, with dynamic tumor size being a predictor for the hazard. Although body weight resulted in higher clearance and lower exposure, simulations showed that an 800 mg flat dose provided optimal response regardless of body weight.

Hexazinone formulated as pellets was applied at three rates (0.3, 0.6, 0.9 lb ai/ac) in a 3-yr-old slash pine (Pinus elliottii Engelm. var. elliottii) plantation in northern Florida to determine herbicide effects on oak competition and subsequent diameter, height, and volume growthof the pines. All three rates significantly reduced the number of oaks, with the reduction linearly related to application rate. Pine growth increased as rate increased and hardwood stocking decreased, although growth for the 0.6 and 0.9 lb/ac rates were not significantly different. Treatmenteffects on growth rates lasted through the first 6 years after herbicide application. The results support the use of the lowest recommended label rates for control of oaks with dry formulations of hexazinone on well-drained sandy soils. South. J. Appl. For. 16(3):133-138.